The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) with NALIRIFOX (NFX) compared to FOLFIRINOX (FFX) in patients not previously treated for metastatic pancreatic ductal adenocarcinoma (mPDAC): An external control arm study.
 
Mei Sheng Duh
Consulting or Advisory Role - Alexion Pharmaceuticals (I); Jazz Pharmaceuticals (I); Omeros (I)
Research Funding - Abbvie (Inst); Apellis Pharmaceuticals (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Humacyte (Inst); IPSEN (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst)
 
Rose Chang
Research Funding - Ipsen (Inst)
 
Paul Cockrum
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Research Funding - Ipsen (Inst)
 
Louise Yu
Research Funding - GlaxoSmithKline (Inst); Ipsen (Inst); Pfizer (Inst)
 
Chunyi Xu
Research Funding - Abbvie (Inst); Alnylam (Inst); Apellis Pharmaceuticals (Inst); AstraZeneca (Inst); Ferring (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Teva (Inst); Travere Therapeutics (Inst)
 
Steven Liu
Stock and Other Ownership Interests - Abbvie; Ascendis Pharma; Biohaven Pharmaceuticals; Krystal Biotech; Lilly; Novo Nordisk; Regeneron; Sanofi
Research Funding - Ipsen (Inst)
 
Eric Maiese
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen